Drug Profile
BI 1323495
Alternative Names: BI-1323495Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antibronchitics; Bronchodilators
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bronchiectasis
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Japan (PO, Tablet)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(Combination therapy, In volunteers) in Germany (PO, Tablet)
- 19 Jan 2022 Boehringer Ingelheim completes phase I trial in Bronchiectasis (Treatment-experienced) (PO) (NCT04656275)